Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Genome Sciences Closes Second Round of Financing

NEW YORK, April 4 (GenomeWeb News) - Oxford Genome Sciences has closed a second round of venture capital investment, the company said today. The size of the investment was not disclosed.

 

Oxfordsaid the financing has allowed it to move into a larger custom-built proteomics facility near Oxford, UK. The funding will also be used to accelerate the company's growth, primarily through partnerships.

 

According to Oxford, the South East Growth Fund, an existing investor, led the round. Oxford Capital Partners participated as a new investor.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.